stockrowRoyalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Net margin
Royalty Pharma PLC's net margin over the twelve months to 30 September 2026 was 0.00%, down 32.4 percentage points from fiscal 2025 (32.4%). Over the past ten years it has ranged from 1.91% (fiscal 2022) to 129.5% (fiscal 2019); the current reading is higher than 38% of that period. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2025 | 32.4% | (5.53) |
| FY2024 | 38.0% | (10.25) |
| FY2023 | 48.2% | 46.29 |
| FY2022 | 1.91% | (25.16) |
| FY2021 | 27.1% | (18.87) |
| FY2020 | 45.9% | (83.51) |
| FY2019 | 129.5% | 52.69 |
| FY2018 | 76.8% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Sep 2026 | 0.00% | (2.65) |
| Jun 2026 | 2.65% | (44.08) |
| Mar 2026 | 46.7% | 12.77 |
| Dec 2025 | 34.0% | (13.34) |
| 25 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| ARGX argenex SE compare | 31.7% |
| GMAB Genmab A/S Sponsored ADR compare | 19.1% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 13.9% |
| INCY Incyte Corporation compare | 6.71% |
| RPRX Royalty Pharma PLC | 0.00% |
| INSM Insmed, Inc. compare | −39.9% |
| BNTX BioNTech SE Sponsored ADR compare | −63.8% |
| RVMD Revolution Medicines, Inc. compare | −894.4% |
| ROIV Roivant Sciences Ltd. compare | −3,535.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement